<p>馬薩諸塞州沃爾瑟姆 --（商業資訊）--Vicarious Surgical Inc.（紐約證券交易所代碼：RBOT）（“公司”）是一家尋求通過變革機器人手術來改善生活的下一代機器人技術公司，今天宣佈已與一家全球數字工程和軟件開發服務公司簽署戰略合作協議。這項合作是公司更廣泛運營模式轉型的核心組成部分，旨在通過更有效的內部和外部工程資源組合，提高執行力、增加開發可預測性，並降低運營費用，正如公司現金消耗指導所反映的那樣。</p>
<p>根據協議，外部工程合作伙伴將負責支持 Vicarious Surgical 機器人系統的軟件開發活動中的重要部分。這包括對控制系統、可視化和關鍵工作流程組件的工程支持。合作伙伴的全球佈局和成熟的工程流程預計將提高開發速度，增強里程碑的可預測性，同時降低結構成本。</p>
<p>Vicarious Surgical 首席執行官 Stephen From 表示：“這項協議增強了我們的執行能力，同時提高了我們運營模式的效率。與一家擁有類似複雜項目規模的組織合作，使我們能夠將內部團隊的重點放在核心創新、系統級集成以及最直接推動我們實現設計凍結和臨牀準備的工作上。”</p>
<p>合作伙伴已通過結構化的過渡計劃開始入駐，該計劃在所有活躍工作流中保持連續性。這項合作與公司優化成本基礎和簡化開發路徑的戰略努力相一致。新的混合結構結合了內部領導與外部執行能力，預計將支持更可預測地朝關鍵里程碑邁進。</p>
<p><strong>關於 Vicarious Surgical</strong></p>
<p>Vicarious Surgical 成立於 2014 年，是一家下一代外科機器人公司，開發了一種獨特的顛覆性技術，旨在大幅提高外科手術的效率、改善患者結果並降低醫療成本。公司的新穎外科方法使用專有的人形外科機器人將外科醫生虛擬運輸到患者體內進行微創手術。公司由一支經驗豐富的技術專家、醫療器械專業人士和醫生團隊領導，並得到了比爾·蓋茨、Vinod Khosla 的 Khosla Ventures、Innovation Endeavors、Jerry Yang 的 AME Cloud Ventures、信興集團和 Philip Liang 的 E15 VC 等科技巨頭的支持。公司總部位於馬薩諸塞州沃爾瑟姆。瞭解更多信息，請訪問 www.vicarioussurgical.com。</p>
<p>根據美國證券交易委員會（SEC）關於公司使用其網站和社交媒體渠道向投資者披露重要信息以及遵守《FD 法規》下的披露義務的指導，公司特此通知投資者、媒體和其他相關方，計劃繼續使用其投資者關係網站（https://investor.vicarioussurgical.com/）、其 LinkedIn 頁面（https://linkedin.com/company/vicarious-surgical/）和其 X feed（@VicariousSurg）發佈有關公司的重要信息，包括可能被視為對投資者重要的信息。公司使用的社交媒體渠道列表可能會不時在其投資者關係網站上更新。公司鼓勵投資者、媒體和其他相關方查看公司在其網站和社交媒體渠道上發佈的信息，以及公司通過 SEC 文件、新聞稿和公開電話會議及網絡廣播宣佈的信息。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1995 年美國私人證券訴訟改革法案 “安全港” 條款的 “前瞻性聲明”。公司的實際結果可能與其預期、估計和預測有所不同，因此，您不應將這些前瞻性聲明視為未來事件的預測。除歷史事實聲明外，本文中包含的所有聲明，包括但不限於關於公司戰略工程參與的預期收益、改善執行和增加開發可預測性的潛力、減少全年運營費用的潛力、預期的開發速度和里程碑可預測性的提高、改善工程產出和效率的潛力、外部工程資源的引入、公司技術改善患者結果的潛力，均為反映管理層當前信念和期望的前瞻性聲明。這些前瞻性聲明涉及重大風險和不確定性，可能導致實際結果與前瞻性聲明中討論的結果有實質性差異。大多數這些因素超出公司的控制範圍，且難以預測。可能導致此類差異的因素包括但不限於：維持公司 A 類普通股在紐約證券交易所上市的能力；公司初始產品候選的批准、商業化和採用，以及其單孔手術機器人 Vicarious Surgical System 的成功及其未來產品候選和服務的成功；適用法律或法規的變化；公司與關鍵第三方（包括外部工程合作伙伴）成功合作的能力，以及利用這些合作關係來管理成本和增加里程碑可預測性的能力；公司未來融資的能力；公司產品和服務開發活動的成功、成本和時間；公司產品候選和服務的潛在屬性和收益；公司獲得和維持 Vicarious Surgical System 的監管批准的能力，以及任何已批准產品的相關限制和條件；Vicarious Surgical System 的人體臨牀試驗的規模和持續時間；公司識別、許可或收購額外技術的能力；公司維持現有許可、製造、供應和分銷協議的能力；公司與其他目前正在營銷或開發與公司當前營銷或開發的產品和服務的公司競爭的能力；公司產品候選和服務市場的規模和增長潛力，以及其單獨或與他人合作服務這些市場的能力；公司產品候選和服務的定價及使用其產品候選和服務進行的醫療程序的報銷；公司對費用、收入、資本需求和額外融資需求的估計；公司的財務表現；經濟衰退、政治和市場條件及其對公司業務、財務狀況和運營結果的潛在不利影響；公司的知識產權及其保護或執行這些權利的能力，以及如果未能做到這一點對其業務、結果和財務狀況的影響；以及公司向 SEC 提交的文件中不時指明的其他風險和不確定性。公司提醒，以上因素清單並不詳盡。公司提醒讀者不要對任何前瞻性聲明過度依賴，這些聲明僅在作出時有效。公司不承擔或接受任何義務或承諾，公開發布任何前瞻性聲明的更新或修訂，以反映其預期的任何變化或任何此類聲明所依據的事件、條件或情況的變化。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjk0NDY5NTJyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjk0NDY5NTJyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251229446952/en/</p>
<p><strong>投資者聯繫</strong></p>
<p>ir@vicarioussurgical.com</p>
<p><strong>媒體諮詢</strong></p>
<p>media@vicarioussurgical.com</p>
<p>來源：Vicarious Surgical Inc.</p>

RBOT

<p>Vicarious Surgical Inc.（紐約證券交易所代碼：RBOT）宣佈與一家全球數字工程公司建立戰略合作伙伴關係，以增強其運營。此次合作旨在通過外包其機器人系統的重要軟件開發活動來改善執行、提高開發可預測性並降低運營成本。首席執行官 Stephen From 強調，這一合作將使內部團隊能夠專注於核心創新。新的混合結構預計將簡化開發路徑，並支持朝着關鍵里程碑的可預測進展</p>

<p>WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has entered into a strategic partnership agreement with a global digital engineering and software development services firm. This engagement is a central component of the Company’s broader operating model transformation, designed to improve execution, increase development predictability, and reduce operating expenses as reflected in the Company’s cash burn guidance, through a more efficient mix of internal and external engineering resources.</p>
<div class="lb-trans"><p>馬薩諸塞州沃爾瑟姆 --（商業資訊）--Vicarious Surgical Inc.（紐約證券交易所代碼：RBOT）（“公司”）是一家尋求通過變革機器人手術來改善生活的下一代機器人技術公司，今天宣佈已與一家全球數字工程和軟件開發服務公司簽署戰略合作協議。這項合作是公司更廣泛運營模式轉型的核心組成部分，旨在通過更有效的內部和外部工程資源組合，提高執行力、增加開發可預測性，並降低運營費用，正如公司現金消耗指導所反映的那樣。</p>
</div><p>Under the agreement, the external engineering partner will assume responsibility for a significant portion of the software development activities that support the Vicarious Surgical robotic system. This includes engineering support for control systems, visualization, and key workflow components. The partner’s global footprint and mature engineering processes are expected to increase development velocity and enhance milestone predictability while lowering structural cost.</p>
<div class="lb-trans"><p>根據協議，外部工程合作伙伴將負責支持 Vicarious Surgical 機器人系統的軟件開發活動中的重要部分。這包括對控制系統、可視化和關鍵工作流程組件的工程支持。合作伙伴的全球佈局和成熟的工程流程預計將提高開發速度，增強里程碑的可預測性，同時降低結構成本。</p>
</div><p>“This agreement strengthens our ability to execute while improving the efficiency of our operating model,” said Stephen From, Chief Executive Officer of Vicarious Surgical. “Partnering with an organization that has scaled programs of similar complexity allows us to focus our internal teams on core innovation, system level integration, and the work that most directly advances us toward design freeze and clinical readiness.”</p>
<div class="lb-trans"><p>Vicarious Surgical 首席執行官 Stephen From 表示：“這項協議增強了我們的執行能力，同時提高了我們運營模式的效率。與一家擁有類似複雜項目規模的組織合作，使我們能夠將內部團隊的重點放在核心創新、系統級集成以及最直接推動我們實現設計凍結和臨牀準備的工作上。”</p>
</div><p>The partner has begun onboarding through a structured transition plan that maintains continuity across all active workstreams. The engagement aligns with the Company’s strategic effort to optimize its cost base and streamline development pathways. The new hybrid structure, which combines internal leadership with external execution capacity, is expected to support more predictable progress toward key milestones.</p>
<div class="lb-trans"><p>合作伙伴已通過結構化的過渡計劃開始入駐，該計劃在所有活躍工作流中保持連續性。這項合作與公司優化成本基礎和簡化開發路徑的戰略努力相一致。新的混合結構結合了內部領導與外部執行能力，預計將支持更可預測地朝關鍵里程碑邁進。</p>
</div><p><strong>About Vicarious Surgical</strong></p>
<div class="lb-trans"><p><strong>關於 Vicarious Surgical</strong></p>
</div><p>Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and has received backing by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai &amp; Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.</p>
<div class="lb-trans"><p>Vicarious Surgical 成立於 2014 年，是一家下一代外科機器人公司，開發了一種獨特的顛覆性技術，旨在大幅提高外科手術的效率、改善患者結果並降低醫療成本。公司的新穎外科方法使用專有的人形外科機器人將外科醫生虛擬運輸到患者體內進行微創手術。公司由一支經驗豐富的技術專家、醫療器械專業人士和醫生團隊領導，並得到了比爾·蓋茨、Vinod Khosla 的 Khosla Ventures、Innovation Endeavors、Jerry Yang 的 AME Cloud Ventures、信興集團和 Philip Liang 的 E15 VC 等科技巨頭的支持。公司總部位於馬薩諸塞州沃爾瑟姆。瞭解更多信息，請訪問 www.vicarioussurgical.com。</p>
</div><p>In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to disclose material information to investors and to comply with its disclosure obligations under Regulation FD, the Company hereby notifies investors, the media and other interested parties that it intends to continue to use its investor relations website (https://investor.vicarioussurgical.com/), its LinkedIn page (https://linkedin.com/company/vicarious-surgical/) and its X feed (@VicariousSurg) to publish important information about the Company, including information that may be deemed material to investors. The list of social media channels that the Company uses may be updated on its investor relations website from time to time. The Company encourages investors, the media, and other interested parties to review the information the Company posts on its website and social media channels as described above, in addition to information announced by the Company through its SEC filings, press releases and public conference calls and webcasts.</p>
<div class="lb-trans"><p>根據美國證券交易委員會（SEC）關於公司使用其網站和社交媒體渠道向投資者披露重要信息以及遵守《FD 法規》下的披露義務的指導，公司特此通知投資者、媒體和其他相關方，計劃繼續使用其投資者關係網站（https://investor.vicarioussurgical.com/）、其 LinkedIn 頁面（https://linkedin.com/company/vicarious-surgical/）和其 X feed（@VicariousSurg）發佈有關公司的重要信息，包括可能被視為對投資者重要的信息。公司使用的社交媒體渠道列表可能會不時在其投資者關係網站上更新。公司鼓勵投資者、媒體和其他相關方查看公司在其網站和社交媒體渠道上發佈的信息，以及公司通過 SEC 文件、新聞稿和公開電話會議及網絡廣播宣佈的信息。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the expected benefits of the Company’s strategic engineering engagement, the potential to improve execution and increase development predictability, the potential of the engagement to reduce full year operating expenses, expected increases in development velocity and milestone predictability, the potential for improved engineering throughput and increased efficiency, the onboarding of external engineering resources, the potential for the Company’s technology to improve patient outcomes, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of the Company’s Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of the Company’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to partner successfully with key third parties including external engineering partners and to leverage those partnerships to manage cost and increase milestone predictability; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s product candidates and services; the Company’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company’s business, financial condition and results of operations; the Company’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company’s filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1995 年美國私人證券訴訟改革法案 “安全港” 條款的 “前瞻性聲明”。公司的實際結果可能與其預期、估計和預測有所不同，因此，您不應將這些前瞻性聲明視為未來事件的預測。除歷史事實聲明外，本文中包含的所有聲明，包括但不限於關於公司戰略工程參與的預期收益、改善執行和增加開發可預測性的潛力、減少全年運營費用的潛力、預期的開發速度和里程碑可預測性的提高、改善工程產出和效率的潛力、外部工程資源的引入、公司技術改善患者結果的潛力，均為反映管理層當前信念和期望的前瞻性聲明。這些前瞻性聲明涉及重大風險和不確定性，可能導致實際結果與前瞻性聲明中討論的結果有實質性差異。大多數這些因素超出公司的控制範圍，且難以預測。可能導致此類差異的因素包括但不限於：維持公司 A 類普通股在紐約證券交易所上市的能力；公司初始產品候選的批准、商業化和採用，以及其單孔手術機器人 Vicarious Surgical System 的成功及其未來產品候選和服務的成功；適用法律或法規的變化；公司與關鍵第三方（包括外部工程合作伙伴）成功合作的能力，以及利用這些合作關係來管理成本和增加里程碑可預測性的能力；公司未來融資的能力；公司產品和服務開發活動的成功、成本和時間；公司產品候選和服務的潛在屬性和收益；公司獲得和維持 Vicarious Surgical System 的監管批准的能力，以及任何已批准產品的相關限制和條件；Vicarious Surgical System 的人體臨牀試驗的規模和持續時間；公司識別、許可或收購額外技術的能力；公司維持現有許可、製造、供應和分銷協議的能力；公司與其他目前正在營銷或開發與公司當前營銷或開發的產品和服務的公司競爭的能力；公司產品候選和服務市場的規模和增長潛力，以及其單獨或與他人合作服務這些市場的能力；公司產品候選和服務的定價及使用其產品候選和服務進行的醫療程序的報銷；公司對費用、收入、資本需求和額外融資需求的估計；公司的財務表現；經濟衰退、政治和市場條件及其對公司業務、財務狀況和運營結果的潛在不利影響；公司的知識產權及其保護或執行這些權利的能力，以及如果未能做到這一點對其業務、結果和財務狀況的影響；以及公司向 SEC 提交的文件中不時指明的其他風險和不確定性。公司提醒，以上因素清單並不詳盡。公司提醒讀者不要對任何前瞻性聲明過度依賴，這些聲明僅在作出時有效。公司不承擔或接受任何義務或承諾，公開發布任何前瞻性聲明的更新或修訂，以反映其預期的任何變化或任何此類聲明所依據的事件、條件或情況的變化。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjk0NDY5NTJyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251229446952r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251229446952/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251229446952/en/</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫</strong></p>
</div><p>ir@vicarioussurgical.com</p>
<div class="lb-trans"><p>ir@vicarioussurgical.com</p>
</div><p><strong>Media Inquiries</strong></p>
<div class="lb-trans"><p><strong>媒體諮詢</strong></p>
</div><p>media@vicarioussurgical.com</p>
<div class="lb-trans"><p>media@vicarioussurgical.com</p>
</div><p>Source: Vicarious Surgical Inc.</p>
<div class="lb-trans"><p>來源：Vicarious Surgical Inc.</p>
</div>

Vicarious Surgical 宣佈戰略軟件執行合作伙伴關係以優化運營 | RBOT 股票新聞